Regeneron has been busy, with two health tech deals announced this week: One is about genetic data and one about AI. Both of ...

Regeneron said it will acquire 23andMe’s genomics service and its bank of 15 million customers’ personal and genetic data as ...

Regeneron acquired 23andMe for $256M, gaining 15M DNA profiles to enhance R&D. Find out why REGN stock is a Buy.

Biotechnology company Regeneron will acquire 23andMe out of bankruptcy for $256 million, with a plan to keep the DNA-testing ...

We recently compiled a list of the 11 Cheap ESG Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands ...

Regeneron Pharmaceuticals said on Monday it will buy genomics firm 23andMe Holding for $256 million through a bankruptcy ...

Regeneron Pharmaceuticals announced initial ... Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make ...

Regeneron Pharmaceuticals signed a deal worth more than $3 billion with contract drug developer Fujifilm Diosynth. Boehringer Ingelheim and Tessellate Bio entered into a research collaboration and ...

The true potential of AI in pharma is its ability to navigate the complexities of bringing AI initiatives to market in a timely manner and managing AI at scale. At ModelOp, we have observed that one ...